Sant’ Anna, B. G.Musolino, N. R.C.Gadelha, M. R.Marques, C.Castro, M.Elias, P. C.L.Vilar, L.Lyra, R.Martins, M. R.A.Quidute, A. R.P.Abucham, J.Nazato, D.Garmes, H. M.Fontana, M. L.C.Boguszewski, C. L.Bueno, C. B.Czepielewski, M. A.Portes, E. S.Nunes-Nogueira, V. S. [UNESP]Ribeiro-Oliveira, A.Francisco, R. P.V.Bronstein, M. D.Glezer, A.2020-12-122020-12-122020-04-01Pituitary, v. 23, n. 2, p. 120-128, 2020.1573-74031386-341Xhttp://hdl.handle.net/11449/201082Objective: To evaluate the maternal–fetal outcomes of CAB-induced pregnancies in patients with prolactinoma in a large cohort. Methods: The prevalence of tumor growth, miscarriage, preterm, low birth weight, congenital malformations and impairment in neuropsychological development in children among women treated with CAB were assessed in a Brazilian multicentre retrospective observational study, Results: We included 194 women with a mean age of 31 (17–45) years, 43.6% presenting microadenomas and 56.4% macroadenomas, at prolactinoma diagnosis. In 233 pregnancies, CAB was withdrawn in 89%, after pregnancy confirmation. Symptoms related to tumor growth occurred in 25 cases, more frequently in macroadenomas. The overall miscarriage rate was 11%, although higher in the subgroup of patients with CAB maintainance after pregnancy confirmation (38% vs. 7.5%). Amongst the live-birth deliveries, preterm occurred in 12%, low birth weight in 6% and congenital malformations in 4.3%. Neuropsychological development impairment was reported in 7% of cases. Conclusions: Our findings confirm previous results of safety in maternal and fetal outcomes in CAB-induced pregnancies; nevertheless, CAB maintenance after pregnancy confirmation was associated with higher miscarriage rate; result that must be further confirmed.120-128engCabergolineDopamine agonistMalformationMiscarriagePregnancyProlactinomaArtigo10.1007/s11102-019-01008-z2-s2.0-85075050448